BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-1501 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-1501\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06588179-11071@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:SHR-1501: Phase 1/2 readout est. (NCT06588179)
DESCRIPTION:SHR-1501\, phase 1/2\, Non-Muscle Invasive Bladder Cancer.\nStu
 dy: SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Blad
 der Cancer Which is Not Completely Resectable by TURBt\nEstimated primary 
 completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/shr-1501#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06588179
URL:https://assetmemo.bio/drug/shr-1501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073534-11071@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SHR-1501: Phase 1/2 readout est. (NCT07073534)
DESCRIPTION:SHR-1501\, phase 1/2.\nStudy: Phase I/II Clinical Study of SHR-
 1501 Combined With Adbelizumab in Patients With Malignant Tumors\nEstimate
 d primary completion: December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/shr-1501#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07073534
URL:https://assetmemo.bio/drug/shr-1501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07726992-11071@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:SHR-1501: Phase 3 readout est. (NCT07726992)
DESCRIPTION:SHR-1501\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy
 : A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BC
 G in Subjects With Papillary-Only NMIBC\nEstimated primary completion: Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-1501#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0772
 6992
URL:https://assetmemo.bio/drug/shr-1501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424287-11071@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:SHR-1501: Phase 3 readout est. (NCT07424287)
DESCRIPTION:SHR-1501\, phase 3.\nStudy: A Study of Intravesical SHR-1501 Co
 mbination With BCG Versus Investigator-selected Chemotherapy in Subjects W
 ith BCG-unresponsive NMIBC\nEstimated primary completion: June 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/shr-1501#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07424287
URL:https://assetmemo.bio/drug/shr-1501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
